1. Home
  2. KD vs ATAI Comparison

KD vs ATAI Comparison

Compare KD & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kyndryl Holdings Inc.

KD

Kyndryl Holdings Inc.

HOLD

Current Price

$13.30

Market Cap

2.8B

Sector

Technology

ML Signal

HOLD

Logo ATAI Life Sciences N.V.

ATAI

ATAI Life Sciences N.V.

HOLD

Current Price

$7.33

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KD
ATAI
Founded
2020
2018
Country
United States
United States
Employees
80000
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.7B
IPO Year
2021
2025

Fundamental Metrics

Financial Performance
Metric
KD
ATAI
Price
$13.30
$7.33
Analyst Decision
Buy
Strong Buy
Analyst Count
7
8
Target Price
$25.92
$15.88
AVG Volume (30 Days)
3.6M
6.6M
Earning Date
05-06-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$15,092,000,000.00
$4,089,000.00
Revenue This Year
$3.73
N/A
Revenue Next Year
$0.08
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.23
1227.60
52 Week Low
$10.10
$3.27
52 Week High
$33.90
$7.45

Technical Indicators

Market Signals
Indicator
KD
ATAI
Relative Strength Index (RSI) 54.44 66.46
Support Level $13.14 $3.56
Resistance Level $13.81 N/A
Average True Range (ATR) 0.54 0.07
MACD 0.01 -0.06
Stochastic Oscillator 76.09 54.76

Price Performance

Historical Comparison
KD
ATAI

About KD Kyndryl Holdings Inc.

Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.

About ATAI ATAI Life Sciences N.V.

AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.

Share on Social Networks: